Skip to main content
Premium Trial:

Request an Annual Quote

Vendor Alliances Heat Up at SBS Conference


GENEVA — At the Society for Biomolecular Screening conference, held here this week, cell-based assay technologies were represented more strongly than at any other time in the 11-year history of the meeting.

More than 300 scientific posters highlighted some of the most cutting-edge research being conducted in the drug screening industry today. The topics of these scientific posters covered a variety of contemporary drug-discovery technologies, but a growing number in particular focused on cell-based assay research.

What's more, many of the posters resulted from collaborations between screening tool vendors and biotech or pharma companies. These presentations are important for tool vendors because, in many cases, they serve to validate a particular instrument platform, reagent line, or assay protocol. And although many of the partners do not have formal business collaborations in place, the alliances could lead to additional partnerships.

Below are some of the key scientific poster collaborations in the areas of cell-based assays that CBA News spotted while roaming the conference floor here last week.

Partners Technologies Poster Title

Acea Biosciences,

Acea's RT-CES instrument Real-time monitoring of morphological changes in living cells using electronic cell sensor arrays: A novel approach to studying G-protein coupled receptors


Cellomics ArrayScan HCS reader and Morphology Explorer bioapplication Identification of kinases affecting downstream phenotypic changes in cell morphology and cytoskeleton by the high-content screening evaluation of an siRNA library*

Pfizer, Cerep

Cellomics KineticScan reader Value of incorporation of an oxidative stress biomarker into high-content screening for human toxicity potential
Corning, Weill Medical College of Cornell University Corning microplates Applications of reverse transfection cell arrays
Evotec Technologies, Genedata Evotec EvoScreen
platform (Mark III and Opera)/Genedata
Screener software
High-content data analysis for a primary confirmation and profiling screen: A case study on multi-parametric µHTS cell imaging data
Evotec Technologies,
Pfizer Global Research
Evotec's Acapella software package (with Molecular Devices' FLIPR) Data analysis: A novel method for analyzing calcium flux kinetics, identifying compound artifacts, and predicting attractive compounds
GE Healthcare,
GE Healthcare, IN Cell Analyzer 3000/Dharmacon siRNA reagents High-content analysis of a reverse transfection siRNA screen using a cell line reporting G1-S cell cycle transition
GE Healthcare,
Banyu (Merck
Japan subsidiary)
GE Healthcare IN Cell Developer Toolbox IN Cell Developer: A flexible software toolbox for analyzing cellular images in automated high-content screening — examples of applications
GE Healthcare, Vanderbilt University IN Cell Analyzer 3000 and 1000 G1-S checkpoint reporting
Hamamatsu FDSS 6000 Data analysis algorithm choice affects both Z-prime factor and hit detection: a case study using FDSS 6000
Molecular Devices, Johnson & Johnson
FDSS 6000/Molecular Devices FLIPR Comparison of HTS systems for measuring intracellular calcium levels
FDSS 6000 Multiplexing non-adherent cells loaded using one of two calcium indicator dyes: Effect on calcium mobilization detection and analysis using the FDSS 6000
Johnson & Johnson
FDSS 6000 Can Aequorin technology reduce false positives in GPCR primary screening?
NIH Chemical
Genomics Center
GeneBlazer and Stealth RNAi Live-cell interrogation of hypoxia-induced signaling
MDS Sciex,
MDS Sciex CellKey Hit-to-lead analysis for GPCR targets using cellular dielectric spectroscopy — a label-free functional cell-based technology
MDS Sciex,
Rigel Pharmaceuticals
CellKey Investigating the FceRI receptor signaling pathway and mast cell degranulation using a novel label-free cell-based assay technology
MDS Sciex,
Johnson & Johnson
CellKey Development of a label-free cellular assays for an endogenously expressed GPCR using cellular dielectric spectroscopy
MDS Sciex,
Hoffman-La Roche
CellKey Complex signaling pathway analysis and pharmacological profiling of a transfected GPCR using cellular dielectric spectroscopy
Molecular Devices,
Molecular Devices FLIPR Tetra/EuroScreen's Aequorin-based luminescence assays FLIPR Tetra and Aequorin-based luminescence assays: IB-MECA stimulated calcium mobilization in CHO-K1 cells expressing adenosine A3 receptor
TTP Labtech,
TTP Labtech's Acumen Explorer/Invitrogen GeneBlazer Detecting the FRET response of the GeneBlazer cell line D1 CRE-bla CHO-K1 to agonists and antagonists using microplate cytometry
TTP Labtech,
Quantum Dot Corporation
Acumen Explorer/Quantum Dots qDot antibody conjugates A high-content primary screening assay identifying multiple protein targets in a cell using quantum dots
TTP Labtech,
Acumen Explorer/Kalypsys Integrated Screening Platform An ultra-high-throughput approach to high-content screening in 1,536-well format
TTP Labtech,
Acumen Explorer/Protedyne BioCube High-throughput automated high-content screening using a BioCube system and microplate cytometry
* Indicates winner of SBS top-10 poster contest


The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.